A Trial Comparing the Safety and Efficacy of Insulin Degludec and Insulin Glargine, With or Without OADs in Subjects With Type 2 Diabetes (SWITCH 2)

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Novo Nordisk A/S
ClinicalTrials.gov Identifier:
NCT02030600
First received: January 7, 2014
Last updated: October 1, 2014
Last verified: October 2014
  Purpose

This trial is conducted in the United States of America (USA). The aim of the trial is to compare the safety and efficacy of insulin degludec (IDeg) and insulin glargine (IGlar) with or without OADs (oral anti-diabetic drugs) excluding SUs (sulfonylureas)/glinides in subjects with type 2 diabetes.


Condition Intervention Phase
Diabetes
Diabetes Mellitus, Type 2
Drug: insulin degludec
Drug: insulin glargine
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Crossover Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: A Randomised, Double Blind, Cross-over Trial Comparing the Safety and Efficacy of Insulin Degludec and Insulin Glargine, With or Without OADs in Subjects With Type 2 Diabetes (SWITCH 2)

Resource links provided by NLM:


Further study details as provided by Novo Nordisk A/S:

Primary Outcome Measures:
  • Number of treatment emergent severe or BG confirmed symptomatic hypoglycaemic episodes during the maintenance period [ Time Frame: After 16 weeks of treatment, in each treatment period (Week 16-32 and Week 48-64) ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Number of treatment emergent severe or BG confirmed symptomatic nocturnal hypoglycaemic during the maintenance period [ Time Frame: After 16 weeks of treatment, in each treatment period (Week 16-32 and Week 48-64) ] [ Designated as safety issue: No ]
  • Proportion of subjects with one or more severe hypoglycaemic episodes during the maintenance period [ Time Frame: After 16 weeks of treatment, in each treatment period (Week 16-32 and Week 48-64) ] [ Designated as safety issue: No ]
  • Incidence of treatment emergent adverse events [ Time Frame: During 32 weeks of treatment for each treatment period ] [ Designated as safety issue: No ]
  • Change from baseline in HbA1c (glycosylated haemoglobin) [ Time Frame: Week 32, Week 64 ] [ Designated as safety issue: No ]
  • FPG (fasting plasma glucose) [ Time Frame: Week 32, Week 64 ] [ Designated as safety issue: No ]

Enrollment: 676
Study Start Date: January 2014
Estimated Study Completion Date: December 2015
Estimated Primary Completion Date: December 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: IDeg OD ± OADs followed by IGlar OD ± OADs
The trial includes two 32-week treatment periods in a cross-over design. Total trial duration for the individual subjects will be up to 67 weeks.
Drug: insulin degludec
Administered once daily injected s.c. / subcutaneously (under the skin). Dose is individually adjusted.
Drug: insulin glargine
Administered once daily injected s.c. / subcutaneously (under the skin). Dose is individually adjusted.
Active Comparator: IGlar OD ± OADs followed by IDeg OD ± OADs
The trial includes two 32-week treatment periods in a cross-over design. Total trial duration for the individual subjects will be up to 67 weeks.
Drug: insulin degludec
Administered once daily injected s.c. / subcutaneously (under the skin). Dose is individually adjusted.
Drug: insulin glargine
Administered once daily injected s.c. / subcutaneously (under the skin). Dose is individually adjusted.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Male or female, age at least 18 years at the time of signing informed consent
  • Subjects fulfilling at least one of the below criteria: a) Experienced at least one severe hypoglycaemic episode within last year (according to the ADA (American Diabetes Association) definition, April 2013), b) Moderate chronic renal failure, defined as glomerular filtration rate 30 - 59 mL/min/1.73 m^2 per CKD-Epi (Chronic Kidney Disease Epidemiology Collaboration) by central laboratory analysis, c) Hypoglycaemic symptom unawareness, d) Exposed to insulin for more than 5 years, e) Recent episode of hypoglycaemia (defined by symptoms of hypoglycaemia and/or episode with low glucose measurement (below or equal to 70 mg/dL [below or equal to 3.9 mmol/L])) within the last 12 weeks prior to Visit 1 (screening)
  • Type 2 diabetes mellitus (diagnosed clinically) for at least 26 weeks prior to Visit 1
  • Current treatment with any basal insulin (OD or BID) ± any combination of OADs (metformin, DPP-4 inhibitor, alpha-glucosidase inhibitor, thiazolidinediones, and SGLT2-inhibitor) for 26 weeks or longer prior to Visit 1 For subjects on BID the total daily dose should be below 75 units
  • HbA1c (glycosylated haemoglobin) below or equal to 9.5 % by central laboratory analysis
  • BMI (body mass index) below or equal to 45 kg/m^2

Exclusion Criteria:

  • Treatment with a bolus insulin separately or contained in an insulin mix product within the last 26 weeks prior to Visit 1
  • Use of any other anti-diabetic agent(s) than those stated in the inclusion criteria within the last 26 weeks prior to Visit 1
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT02030600

  Hide Study Locations
Locations
United States, Alabama
Novo Nordisk Clinical Trial Call Center
Birmingham, Alabama, United States, 35216
Novo Nordisk Clinical Trial Call Center
Birmingham, Alabama, United States, 35215-7502
Novo Nordisk Clinical Trial Call Center
Haleyville, Alabama, United States, 35565-1719
Novo Nordisk Clinical Trial Call Center
Montgomery, Alabama, United States, 36106-1509
United States, Arizona
Novo Nordisk Clinical Trial Call Center
Phoenix, Arizona, United States, 85050
Novo Nordisk Clinical Trial Call Center
Phoenix, Arizona, United States, 85013
United States, Arkansas
Novo Nordisk Clinical Trial Call Center
Little Rock, Arkansas, United States, 72205
United States, California
Novo Nordisk Clinical Trial Call Center
Chino, California, United States, 91710
Novo Nordisk Clinical Trial Call Center
Costa Mesa, California, United States, 92626
Novo Nordisk Clinical Trial Call Center
Downey, California, United States, 90242
Novo Nordisk Clinical Trial Call Center
El Cajon, California, United States, 92020
Novo Nordisk Clinical Trial Call Center
Fair Oaks, California, United States, 95628
Novo Nordisk Clinical Trial Call Center
Fresno, California, United States, 93720
Novo Nordisk Clinical Trial Call Center
Fresno, California, United States, 93702
Novo Nordisk Clinical Trial Call Center
Hawaiian Gardens, California, United States, 90716
Novo Nordisk Clinical Trial Call Center
Huntington Park, California, United States, 90255
Novo Nordisk Clinical Trial Call Center
Lincoln, California, United States, 95648
Novo Nordisk Clinical Trial Call Center
Long Beach, California, United States, 90807
Novo Nordisk Clinical Trial Call Center
Northridge, California, United States, 91325
Novo Nordisk Clinical Trial Call Center
Pomona, California, United States, 91766-1854
Novo Nordisk Clinical Trial Call Center
Rancho Cucamonga, California, United States, 91730-3063
Novo Nordisk Clinical Trial Call Center
Rialto, California, United States, 92376
Novo Nordisk Clinical Trial Call Center
San Diego, California, United States, 92111
Novo Nordisk Clinical Trial Call Center
Santa Monica, California, United States, 90404
Novo Nordisk Clinical Trial Call Center
Tarzana, California, United States, 91356-3551
Novo Nordisk Clinical Trial Call Center
Tustin, California, United States, 92780
United States, Colorado
Novo Nordisk Clinical Trial Call Center
Golden, Colorado, United States, 80401
United States, Florida
Novo Nordisk Clinical Trial Call Center
Bradenton, Florida, United States, 34208
Novo Nordisk Clinical Trial Call Center
Chiefland, Florida, United States, 32626
Novo Nordisk Clinical Trial Call Center
Clearwater, Florida, United States, 33756
Novo Nordisk Clinical Trial Call Center
Clearwater, Florida, United States, 33765
Novo Nordisk Clinical Trial Call Center
Cooper City, Florida, United States, 33024
Novo Nordisk Clinical Trial Call Center
Doral, Florida, United States, 33166
Novo Nordisk Clinical Trial Call Center
Doral, Florida, United States, 33172
Novo Nordisk Clinical Trial Call Center
Hialeah, Florida, United States, 33012
Novo Nordisk Clinical Trial Call Center
Hialeah, Florida, United States, 33013
Novo Nordisk Clinical Trial Call Center
Jacksonville, Florida, United States, 32256
Novo Nordisk Clinical Trial Call Center
Jacksonville, Florida, United States, 32216
Novo Nordisk Clinical Trial Call Center
Jacksonville, Florida, United States, 32204
Novo Nordisk Clinical Trial Call Center
Jacksonville, Florida, United States, 32277
Novo Nordisk Clinical Trial Call Center
Miami, Florida, United States, 33186
Novo Nordisk Clinical Trial Call Center
Miami, Florida, United States, 33130
Novo Nordisk Clinical Trial Call Center
Miami, Florida, United States, 33155
Novo Nordisk Clinical Trial Call Center
Miami, Florida, United States, 33175
Novo Nordisk Clinical Trial Call Center
Miami, Florida, United States, 33156
Novo Nordisk Clinical Trial Call Center
Miami, Florida, United States, 33174
Novo Nordisk Clinical Trial Call Center
Miami Springs, Florida, United States, 33166
Novo Nordisk Clinical Trial Call Center
Miramar, Florida, United States, 33027
Novo Nordisk Clinical Trial Call Center
New Port Richey, Florida, United States, 34652
Novo Nordisk Clinical Trial Call Center
Ocala, Florida, United States, 34471
Novo Nordisk Clinical Trial Call Center
Orlando, Florida, United States, 32801
Novo Nordisk Clinical Trial Call Center
Panama City, Florida, United States, 32401
Novo Nordisk Clinical Trial Call Center
Pembroke Pines, Florida, United States, 33026
Novo Nordisk Clinical Trial Call Center
Tampa, Florida, United States, 33607
Novo Nordisk Clinical Trial Call Center
Tampa, Florida, United States, 33619
United States, Georgia
Novo Nordisk Clinical Trial Call Center
Perry, Georgia, United States, 31069
United States, Illinois
Novo Nordisk Clinical Trial Call Center
Champaign, Illinois, United States, 61820
Novo Nordisk Clinical Trial Call Center
Chicago, Illinois, United States, 60611
United States, Indiana
Novo Nordisk Clinical Trial Call Center
Evansville, Indiana, United States, 47714
Novo Nordisk Clinical Trial Call Center
Muncie, Indiana, United States, 47304
United States, Iowa
Novo Nordisk Clinical Trial Call Center
Des Moines, Iowa, United States, 50314-2610
United States, Kansas
Novo Nordisk Clinical Trial Call Center
Lenexa, Kansas, United States, 66219
Novo Nordisk Clinical Trial Call Center
Newton, Kansas, United States, 67114
United States, Kentucky
Novo Nordisk Clinical Trial Call Center
Lexington, Kentucky, United States, 40503
Novo Nordisk Clinical Trial Call Center
Lexington, Kentucky, United States, 40502
Novo Nordisk Clinical Trial Call Center
Louisville, Kentucky, United States, 40218
Novo Nordisk Clinical Trial Call Center
Paducah, Kentucky, United States, 42003
United States, Louisiana
Novo Nordisk Clinical Trial Call Center
New Orleans, Louisiana, United States, 70119
United States, Massachusetts
Novo Nordisk Clinical Trial Call Center
Brockton, Massachusetts, United States, 02301
United States, Michigan
Novo Nordisk Clinical Trial Call Center
Kalamazoo, Michigan, United States, 49009
United States, Mississippi
Novo Nordisk Clinical Trial Call Center
Olive Branch, Mississippi, United States, 38654-3573
United States, Missouri
Novo Nordisk Clinical Trial Call Center
Florissant, Missouri, United States, 63031
Novo Nordisk Clinical Trial Call Center
Jefferson City, Missouri, United States, 65109-6001
United States, Nevada
Novo Nordisk Clinical Trial Call Center
Henderson, Nevada, United States, 89052-2649
Novo Nordisk Clinical Trial Call Center
Las Vegas, Nevada, United States, 89148
United States, New Jersey
Novo Nordisk Clinical Trial Call Center
Morganville, New Jersey, United States, 07751
Novo Nordisk Clinical Trial Call Center
Teaneck, New Jersey, United States, 07666
United States, New Mexico
Novo Nordisk Clinical Trial Call Center
Albuquerque, New Mexico, United States, 87102
United States, New York
Novo Nordisk Clinical Trial Call Center
Albany, New York, United States, 12208
Novo Nordisk Clinical Trial Call Center
Jackson Heights, New York, United States, 11372
Novo Nordisk Clinical Trial Call Center
New Windsor, New York, United States, 12553
Novo Nordisk Clinical Trial Call Center
Northport, New York, United States, 11768
Novo Nordisk Clinical Trial Call Center
Smithtown, New York, United States, 11787
United States, North Carolina
Novo Nordisk Clinical Trial Call Center
Charlotte, North Carolina, United States, 28277
United States, Ohio
Novo Nordisk Clinical Trial Call Center
Delaware, Ohio, United States, 43015
Novo Nordisk Clinical Trial Call Center
Franklin, Ohio, United States, 45005
Novo Nordisk Clinical Trial Call Center
Toledo, Ohio, United States, 43614
United States, Oklahoma
Novo Nordisk Clinical Trial Call Center
Oklahoma City, Oklahoma, United States, 73103
United States, Pennsylvania
Novo Nordisk Clinical Trial Call Center
Beaver, Pennsylvania, United States, 15009
Novo Nordisk Clinical Trial Call Center
Philadelphia, Pennsylvania, United States, 19152
Novo Nordisk Clinical Trial Call Center
Philadelphia, Pennsylvania, United States, 19107
Novo Nordisk Clinical Trial Call Center
Scottdale, Pennsylvania, United States, 15683
Novo Nordisk Clinical Trial Call Center
Tipton, Pennsylvania, United States, 16684
United States, South Carolina
Novo Nordisk Clinical Trial Call Center
Gaffney, South Carolina, United States, 29341
Novo Nordisk Clinical Trial Call Center
Greenville, South Carolina, United States, 29615
Novo Nordisk Clinical Trial Call Center
Pelzer, South Carolina, United States, 29669
United States, South Dakota
Novo Nordisk Clinical Trial Call Center
Rapid City, South Dakota, United States, 57701
United States, Tennessee
Novo Nordisk Clinical Trial Call Center
Bristol, Tennessee, United States, 37620
Novo Nordisk Clinical Trial Call Center
Bristol, Tennessee, United States, 37620-7352
Novo Nordisk Clinical Trial Call Center
Chattanooga, Tennessee, United States, 37404
Novo Nordisk Clinical Trial Call Center
Humboldt, Tennessee, United States, 38343
Novo Nordisk Clinical Trial Call Center
Jackson, Tennessee, United States, 38305
Novo Nordisk Clinical Trial Call Center
Johnson City, Tennessee, United States, 37604
Novo Nordisk Clinical Trial Call Center
Kingsport, Tennessee, United States, 37660
United States, Texas
Novo Nordisk Clinical Trial Call Center
Arlington, Texas, United States, 76012-4637
Novo Nordisk Clinical Trial Call Center
Arlington, Texas, United States, 76012
Novo Nordisk Clinical Trial Call Center
Austin, Texas, United States, 78758
Novo Nordisk Clinical Trial Call Center
Carrollton, Texas, United States, 75007
Novo Nordisk Clinical Trial Call Center
Dallas, Texas, United States, 75208
Novo Nordisk Clinical Trial Call Center
El Paso, Texas, United States, 79925
Novo Nordisk Clinical Trial Call Center
Fort Worth, Texas, United States, 76104
Novo Nordisk Clinical Trial Call Center
Houston, Texas, United States, 77070
Novo Nordisk Clinical Trial Call Center
Houston, Texas, United States, 77072
Novo Nordisk Clinical Trial Call Center
Houston, Texas, United States, 77060
Novo Nordisk Clinical Trial Call Center
Houston, Texas, United States, 77036
Novo Nordisk Clinical Trial Call Center
Houston, Texas, United States, 77043
Novo Nordisk Clinical Trial Call Center
Houston, Texas, United States, 77077
Novo Nordisk Clinical Trial Call Center
Humble, Texas, United States, 77338
Novo Nordisk Clinical Trial Call Center
Hurst, Texas, United States, 76054
Novo Nordisk Clinical Trial Call Center
Marshall, Texas, United States, 75670
Novo Nordisk Clinical Trial Call Center
Mesquite, Texas, United States, 75149
Novo Nordisk Clinical Trial Call Center
North Richland Hills, Texas, United States, 76180
Novo Nordisk Clinical Trial Call Center
Plano, Texas, United States, 75093
Novo Nordisk Clinical Trial Call Center
Plano, Texas, United States, 75075
Novo Nordisk Clinical Trial Call Center
San Antonio, Texas, United States, 78224
Novo Nordisk Clinical Trial Call Center
San Antonio, Texas, United States, 78229
Novo Nordisk Clinical Trial Call Center
San Antonio, Texas, United States, 78215
Novo Nordisk Clinical Trial Call Center
San Antonio, Texas, United States, 78258
Novo Nordisk Clinical Trial Call Center
San Antonio, Texas, United States, 78228-3419
Novo Nordisk Clinical Trial Call Center
San Antonio, Texas, United States, 78240
Novo Nordisk Clinical Trial Call Center
Sugarland, Texas, United States, 77478
Novo Nordisk Clinical Trial Call Center
Victoria, Texas, United States, 77901
Novo Nordisk Clinical Trial Call Center
Waco, Texas, United States, 76710
United States, Utah
Novo Nordisk Clinical Trial Call Center
Draper, Utah, United States, 84020
Novo Nordisk Clinical Trial Call Center
Ogden, Utah, United States, 84405
Novo Nordisk Clinical Trial Call Center
Salt Lake City, Utah, United States, 84107
United States, Virginia
Novo Nordisk Clinical Trial Call Center
Chesapeake, Virginia, United States, 23321
Novo Nordisk Clinical Trial Call Center
Norfolk, Virginia, United States, 23510
United States, Washington
Novo Nordisk Clinical Trial Call Center
Olympia, Washington, United States, 98502
Novo Nordisk Clinical Trial Call Center
Renton, Washington, United States, 98057
Novo Nordisk Clinical Trial Call Center
Spokane, Washington, United States, 99202-3649
United States, West Virginia
Novo Nordisk Clinical Trial Call Center
Martinsburg, West Virginia, United States, 25401
United States, Wisconsin
Novo Nordisk Clinical Trial Call Center
Kenosha, Wisconsin, United States, 53142-7884
Puerto Rico
Novo Nordisk Clinical Trial Call Center
Carolina, Puerto Rico, 00983
Novo Nordisk Clinical Trial Call Center
Manati, Puerto Rico, 00674
Novo Nordisk Clinical Trial Call Center
Ponce, Puerto Rico, 00717
Novo Nordisk Clinical Trial Call Center
San Juan, Puerto Rico, 00921
Novo Nordisk Clinical Trial Call Center
San Juan, Puerto Rico, 00918
Sponsors and Collaborators
Novo Nordisk A/S
Investigators
Study Director: Global Clinical Registry (GCR, 1452) Novo Nordisk A/S
  More Information

Additional Information:
No publications provided

Responsible Party: Novo Nordisk A/S
ClinicalTrials.gov Identifier: NCT02030600     History of Changes
Other Study ID Numbers: NN1250-3998, U1111-1143-7963
Study First Received: January 7, 2014
Last Updated: October 1, 2014
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 2
Endocrine System Diseases
Glucose Metabolism Disorders
Metabolic Diseases
Glargine
Insulin
Insulin, Globin Zinc
Insulin, Long-Acting
Hypoglycemic Agents
Pharmacologic Actions
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on October 23, 2014